Has FDG PET/CT an impact on the management of patients with anal carcinoma?;La TEP/TDM au FDG a-t-elle un impact dans la prise en charge des patients atteints d'un cancer du canal anal ?

Medecine Nucleaire

Volumn 34, Issue 2, 2010, Pages 96-102

  Vercellino, L ^a   de Parades, V ^b   Nataf, V ^a   Kerrou, K ^a   Huchet, V ^a   Bauer, P ^b   Pascal, O ^a   Touboul, E ^a   Montravers, F ^a   Talbot, J N ^a  

^a HÔPITAL TENON   (France)

^b GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

Author keywords

Anal carcinoma; FDG; Impact on management; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANUS CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLOW UP; HUMAN; POSITRON EMISSION TOMOGRAPHY;

EID: 84865697607     PISSN: 09281258     EISSN: 18786820     Source Type: Journal    
DOI: 10.1016/j.mednuc.2009.12.005     Document Type: Article

References (30)

1. Bedenne L., Janoray I., Arveux P., Horiot J.C., Janoray P., Ledorze C., et al. Le cancer épidermoïde du canal anal dans le département de la Côte d'Or. Gastroenterol Clin Biol 1989, 15:130-136.
2. Johnson L.G., Madeleine M.M., Newcomer L.M., Schwartz S.M., Daling J.R. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004, 101:281-288.
3. Welton M.L., Sharkey F.E., Kahlenberg M.S. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am 2004, 13:263-275.
4. Fleshner P.R., Chalasani S., Chang G.J., Levien D.H., Hyman N.H., Buie W.D. Practice parameters for anal squamous neoplasms Standards Practice Task Force. American Society of Colon and Rectal Surgeons. Dis Colon Rectum 2008, 51:2-9.
5. Goldman S., Norming U., Svensson C., Glimelius B. Transanorectal ultrasonography in the staging of anal epidermoid carcinoma. Int J Colorectal Dis 1991, 6:152-157.
6. Scherrer A., Reboul F., Martin D., Dupuy J.C., Menu Y. CT of malignant anal canal tumors. Radiographics 1990, 10:433-453.
7. Roach S.C., Hulse P.A., Moulding F.J., Wilson R., Carrington B.M. Magnetic resonance imaging of anal cancer. Clin Radiol 2005, 60:1111-1119.
8. Gretschel S., Warnick P., Bembenek A., Dresel S., Koswig S., String A., et al. Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol 2008, 34:890-894.
9. Bartelink H., Roelofsen F., Eschwege F., Rougier P., Bosset J.F., Gonzalez D.G., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040-2049.
10. Sato H., Koh P.K., Bartolo D.C. Management of anal canal cancer. Dis Colon Rectum 2005, 48:1301-1315.
11. Das P., Bhatia S., Eng C., Ajani J.A., Skibber J.M., Rodriguez-Bigas M.A., et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007, 68:794-800.
12. Ghouti L., Houvenaeghel G., Moutardier V., Giovannini M., Magnin V., Lelong B., et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum 2005, 48:16-22.
13. Christensen A.F., Nielsen M.B., Svendsen L.B., Engelholm S.A. Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum 2006, 49:1527-1532.
14. Shankar L.K., Hoffman J.M., Bacharach S., Graham M.M., Karp J., Lammertsma A.A., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006, 47:1059-1066.
15. Trautmann T.G., Zuger J.H. Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005, 7:309-313.
16. Anderson C., Koshy M., Staley C., Esiashvili N., Ghavidel S., Fowler Z., et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 2007, 69:155-162.
17. Cotter S.E., Grigsby P.W., Siegel B.A., Dehdashti F., Malyapa R.S., Fleshman J.W., et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006, 65(3):720-725.
18. Nguyen B.T., Joon D.L., Khoo V., Quong G., Chao M., Wada M., et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 2008, 87:376-382.
19. Schwarz J.K., Siegel B.A., Dehdashti F., Myerson R.J., Fleshman J.W., Grigsby P.W. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008, 71:180-186.
20. De Winton E., Heriot A.G., Ng M., Hicks R.J., Hogg A., Milner A., et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 2009, 100:693-700.
21. 18F-fluorodéoxyglucose (TEP-FDG) dans la prise en charge du cancer du canal anal. Med Nucl 2009, 33:415-424.
22. Mai S.K., Welzel G., Hermann B., Wenz F., Haberkorn U., Dinter D.J. Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced?. Strahlenther Onkol 2009, 185:254-259.
23. Mistrangelo M., Pelosi E., Bellò M., Castellano I., Cassoni P., Ricardi U., et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys 2009, [Epub ahead of print].
24. van Waarde A., Cobben D.C., Suurmeijer A.J., Maas B., Vaalburg W., de Vries E.F., et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004, 45:695-700.
25. Goshen E., Davidson T., Avigdor A., Zwas T.S., Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med 2008, 33:610-614.
26. Vatra B., Sobhani I., Aparicio T., Girard P.M., Puy Montbrun T.D., Housset M., et al. Caractéristiques clinique, thérapeutiques et pronostiques des carcinomes épidermoïdes du canal anal chez les malades VIH positifs [Anal canal squamous-cell carcinomas in HIV positive patients: clinical features, treatments and prognosis]. Gastroenterol Clin Biol 2002, 26:150-156.
27. Burgi A., Brodine S., Wegner S., Ilazzo M., Wallace M.R., Spooner K., et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005, 104:1505-1511.
28. Scharko A.M., Perlman S.B., Pyzalski R.W., Graziano F.M., Sosman J., Pauza C.D. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 2003, 362:959-961.
29. Lucignani G., Orunesu E., Cesari M., Marzo K., Pacei M., Bechi G., et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging 2009, 36:640-647.
30. Grigsby P.W. FDG-PET/CT: New horizons in anal cancer. Gastroenterol Clin Biol 2009, 33:456-458.